Negative outcomes associated with adding anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to chemotherapybevacizumab combination therapy in patients with metastatic colorectal cancer

American Journal of Hematology/ Oncology

Volumn 8, Issue 9, 2009, Pages

  Dillman, Robert O ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIGEN BINDING; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG MECHANISM; HUMAN; METASTASIS; NOTE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION;

EID: 73649103125     PISSN: 15429520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (30)

1. Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol. 2008;26:1774-1777.
2. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
4. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502-3508.
5. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-3705.
6. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
7. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of effi cacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706-3712.
8. Giantonio BJ, Levy DE, O'Dwyer PJ, et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol. 2006;17:1399-1403.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
10. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24:4914-4921.
11. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.
12. Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for fi rst-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6:427-432.
13. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664.
14. Giusti RM, Shastri KA, Cohen MH, et al. FDA drug approval summary: panitumumab (Vectibix). Oncologist. 2007;12:577-583.
15. Dillman RO, Shawler DL, Johnson DE, et al. Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. 1986;46:4886 4891.
16. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med. 1989;111:592 603.
17. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol. 1994;12:1497-1515.
18. Dillman RO. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 2001;19:833-841.
19. Dillman RO, Johnson DE, Shawler DL, et al. Superiority of an acid labile daunorubicin monoclonal antibody immunoconjugate compared to free drug. Cancer Res. 1988;48:6097 6102.
20. Dillman RO, Johnson DE, Ogden J, et al. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. Mol Biother. 1989;1:250-255.
21. Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol. 2009;7:45-53.
22. Miller FR. Intratumor immunologic heterogeneity. Cancer Metastasis Rev. 1982;1:319-334.
23. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer. 2001;85: 584-589.
24. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res. 2006;12:2197-2207.
25. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer. 2007;8(suppl 2):S79-S85.
26. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25:4557-4561.
27. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563-572.
28. Mayer RJ. Targeted therapy for advanced colorectal cancer-more is not always better. N Engl J Med. 2009;360:623-625.
29. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-680.
30. Blanke CD. Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may. J Clin Oncol. 2009;27: 655-658.